It’s not always easy to figure out whether information coming from pharmaceutical companies is promising or should be considered a setback. That was the case in recent weeks as the hair loss community has tried to decipher information released by the Swiss company, Polichem, related to its Phase III clinical trial of P-3074. That’s the working name for the topical finasteride compound Polichem has been developing and testing for years.This spring the company published, Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia, which reported findings from its trial. It was a bit unusual, however, because the published results lacked a written analysis or conclusion. As a result, interested people who have been follow
↧